Stock Track | Hims & Hers Health Soars 9.08% Pre-Market on Surging Demand for Wegovy Alternatives

Stock Track11-25

Hims & Hers Health Inc. (HIMS) saw its stock surge 9.08% in pre-market trading on Monday, driven by the soaring demand for alternative versions of the popular weight-loss drug Wegovy, which the telehealth provider offers.

According to industry reports, more than 200,000 prescriptions for compounded copies of Wegovy are being filled each month in the U.S., as patients turn to these alternatives due to shortages and high costs of the branded drug. Hims & Hers is among the telehealth providers offering these compounded versions, potentially benefiting from the rising demand.

The surge in demand for Wegovy alternatives comes as the FDA weighs whether to remove the drug from its shortage list, which has allowed compounding pharmacies to produce and sell their own versions. If removed from the list, these pharmacies may be forced to halt production, potentially driving more patients to seek out alternatives like those offered by Hims & Hers.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1143217319?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-25 22:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1143217319","market":"us","top_or_hot":-1,"title":"Stock Track | Hims & Hers Health Soars 9.08% Pre-Market on Surging Demand for Wegovy Alternatives","media":"Stock Track","content":"<p>Hims & Hers Health Inc. (HIMS) saw its stock surge 9.08% in pre-market trading on Monday, driven by the soaring demand for alternative versions of the popular weight-loss drug Wegovy, which the telehealth provider offers.</p>\n\n<p>According to industry reports, more than 200,000 prescriptions for compounded copies of Wegovy are being filled each month in the U.S., as patients turn to these alternatives due to shortages and high costs of the branded drug. Hims & Hers is among the telehealth providers offering these compounded versions, potentially benefiting from the rising demand.</p>\n\n<p>The surge in demand for Wegovy alternatives comes as the FDA weighs whether to remove the drug from its shortage list, which has allowed compounding pharmacies to produce and sell their own versions. If removed from the list, these pharmacies may be forced to halt production, potentially driving more patients to seek out alternatives like those offered by Hims & Hers.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Hims & Hers Health Soars 9.08% Pre-Market on Surging Demand for Wegovy Alternatives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Hims & Hers Health Soars 9.08% Pre-Market on Surging Demand for Wegovy Alternatives\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-25 22:34 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Hims & Hers Health Inc. (HIMS) saw its stock surge 9.08% in pre-market trading on Monday, driven by the soaring demand for alternative versions of the popular weight-loss drug Wegovy, which the ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1143217319","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1143217319","pubTimestamp":1732545269,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Hims & Hers Health Inc.  saw its stock surge 9.08% in pre-market trading on Monday, driven by the soaring demand for alternative versions of the popular weight-loss drug Wegovy, which the telehealth provider offers.According to industry reports, more than 200,000 prescriptions for compounded copies of Wegovy are being filled each month in the U.S., as patients turn to these alternatives due to shortages and high costs of the branded drug. Hims & Hers is among the telehealth providers offering th","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"由于对Wegovy替代品的需求激增，Hims&Hers Health盘前飙升9.08%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"Hims & Hers Health Inc. (HIMS) saw its stock surge 9.08% in pre-market trading on Monday, driven by the soaring demand for alternative versions of the popular weight-loss drug Wegovy, which the telehealth provider offers.\nAccording to industry reports, more than 200,000 prescriptions for compounded copies of Wegovy are being filled each month in the U.S., as patients turn to these alternatives due to shortages and high costs of the branded drug. Hims & Hers is among the telehealth providers offering these compounded versions, potentially benefiting from the rising demand.\nThe surge in demand for Wegovy alternatives comes as the FDA weighs whether to remove the drug from its shortage list, which has allowed compounding pharmacies to produce and sell their own versions. If removed from the list, these pharmacies may be forced to halt production, potentially driving more patients to seek out alternatives like those offered by Hims & Hers.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1143217319"}